Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $65.3 million.

  • Phathom Pharmaceuticals' Accumulated Expenses rose 8274.84% to $65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.3 million, marking a year-over-year increase of 8274.84%. This contributed to the annual value of $53.2 million for FY2024, which is 20954.24% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Accumulated Expenses stood at $65.3 million for Q3 2025, which was up 8274.84% from $64.3 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Accumulated Expenses ranged from a high of $65.3 million in Q3 2025 and a low of $7.6 million during Q1 2022
  • Moreover, its 4-year median value for Accumulated Expenses was $16.5 million (2024), whereas its average is $27.3 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Accumulated Expenses soared by 124.92% in 2023, and later soared by 20954.24% in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Accumulated Expenses (Quarter) stood at $14.7 million in 2022, then increased by 17.16% to $17.2 million in 2023, then soared by 209.54% to $53.2 million in 2024, then grew by 22.76% to $65.3 million in 2025.
  • Its Accumulated Expenses stands at $65.3 million for Q3 2025, versus $64.3 million for Q2 2025 and $43.0 million for Q1 2025.